NextCure's macrophage-based alternative to T cell checkpoint inhibitors

A study led by NextCure co-founder and PD-1 pioneer Lieping Chen has found that blocking SIGLEC15 could boost antitumor T cell responses in immunosuppressive tumor microenvironments.

NextCure Inc.

Read the full 287 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE